Secrets of High Blood Pressure Treatment
Medical scientists are fighting this life-threatening disease and they have gained some success. That is the development of several classes of antihypertensive drugs and definition of “normal” levels of blood pressure that should be maintained to reduce the risk of cardiovascular complications and death.
Is it a great success? Unfortunately not. Pharmaceutical treatment can not reverse the disease. The patient with developed arterial hypertension can only hope to reduce the risk of high blood pressure complications. How big is this risk reduction? Relative risk reduction is less than 25% during 2-5 years for all major cardiovascular complications. It is higher for stroke (36-45%) and less for heart attacks (10-15%). When all risks are combined, the relative risk reduction is close to 25%.
Be careful and distinguish absolute and relative risk reductions. Papers and pharmaceutical ads always present relative risk reduction which is more impressive. They even do not mention that it is “relative”. That is because the absolute risk reduction could be as much as 0.2-2.0%. Does not impress you, right? Let’s take a clinical trial where 0.6% and 0.96% of patients had had fatal stroke in the treatment group and placebo group accordingly. Absolute risk reduction will be 0.96% - 0.60% = 0.36%, however relative risk reduction will be as much as (0.96% - 0.6%)/0.96% = 37.5%! Looks much better! Absolute risk reduction 0.36% means that from one thousand patients taking medication during 3-5 years, three or four could be saved from fatal stroke. Clinical trials don’t say what will happen with those saved patients after 5 years. Presumably, the risk is postponed towards after 5 years period. Clinical trials also do not say which particular patients will be saved. It is like lottery, it could happen that 4 saved patients is just a difference between 44 saved and 40 preliminary died due to pharmaceutical side effects. Vioxx, Celebrex, Baycol are the known examples.
Medical scientists are fighting this life-threatening disease and they have gained some success. That is the development of several classes of antihypertensive drugs and definition of “normal” levels of blood pressure that should be maintained to reduce the risk of cardiovascular complications and death.
Is it a great success? Unfortunately not. Pharmaceutical treatment can not reverse the disease. The patient with developed arterial hypertension can only hope to reduce the risk of high blood pressure complications. How big is this risk reduction? Relative risk reduction is less than 25% during 2-5 years for all major cardiovascular complications. It is higher for stroke (36-45%) and less for heart attacks (10-15%). When all risks are combined, the relative risk reduction is close to 25%.
Be careful and distinguish absolute and relative risk reductions. Papers and pharmaceutical ads always present relative risk reduction which is more impressive. They even do not mention that it is “relative”. That is because the absolute risk reduction could be as much as 0.2-2.0%. Does not impress you, right? Let’s take a clinical trial where 0.6% and 0.96% of patients had had fatal stroke in the treatment group and placebo group accordingly. Absolute risk reduction will be 0.96% - 0.60% = 0.36%, however relative risk reduction will be as much as (0.96% - 0.6%)/0.96% = 37.5%! Looks much better! Absolute risk reduction 0.36% means that from one thousand patients taking medication during 3-5 years, three or four could be saved from fatal stroke. Clinical trials don’t say what will happen with those saved patients after 5 years. Presumably, the risk is postponed towards after 5 years period. Clinical trials also do not say which particular patients will be saved. It is like lottery, it could happen that 4 saved patients is just a difference between 44 saved and 40 preliminary died due to pharmaceutical side effects. Vioxx, Celebrex, Baycol are the known examples.
